✦ LIBER ✦

1264 Cytokeratin 19 soluble fragments (CK19) determination in patients with non-small cell lung cancer (NSCLC): Comparison with TPA, CEA, SCC and NSE

✍ Scribed by Foa, P.; Seregni, E.; Santambrogio, L.; Mezzetti, M.; Sala, M.; Iurlo, A.; Bombardieri, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation between serum cytokeratin 19

✍ Kosuke Kashiwabara; Hiroyuki Nakamura; Toshio Kiguchi; Hisanaga Yagyu; Koji Kish 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 55 KB

P-121 What is the clinical significance

✍ Szturmowicz, M.; Rudzinski, P.; Kacpizak, A.; Langfort, R.; Bestry, I.; Demkow, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 294 KB

Serum Sialyl Lewisx and cytokeratin 19 f

✍ Mizuguchi, Shinjiro; Nishiyama, Noritoshi; Iwata, Takashi; Nishida, Tatsuya; Izu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Clinical evaluation of NSE, TPA and CEA

📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Tumor markers (CEA, CA 125, CYFRA 21.1,

✍ Vinolas, N; Molina, R; Fuentes, R; Bover, I; Rifa, J; Moreno, V; Canals, E; Marq 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 121 KB

6554 POSTER Serum sialyl Lewisx and cyto

✍ Mizuguchi, S.; Nishiyama, N.; Iwata, T.; Nishida, T.; Izumi, N.; Tsukioka, T.; I 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB